Skip to main content

Advertisement

Table 1 Baseline characteristics of 189 breast cancer patients with brain metastases

From: Clinical implication of Time To Brain Metastasis (TTBM) according to breast cancer subtypes

Characteristics Total N=189 (%)
Median age (range)  
 at initial diagnosis of distant metastasis 46 (25–85)
 at initial diagnosis of BM 48 (26–87)
Menopausal status at initial diagnosis  
 premenopausal 104 (55%)
 postmenopausal 42 (22%)
 unknown 43 (23%)
Histology  
 Invasive ductal carcinoma 163 (86%)
 Invasive lobular carcinoma 3 (2%)
 Others 10 (5%)
 Unknown 13 (7%)
Stage at initial diagnosis  
 I/II 81 (43%)
 III 76 (40%)
 IV 18 (10%)
 unknown 14 (7%)
Tumor subtype  
 HR-positive/HER2-negative 45 (23%)
 HER2-positive irrespective of HR status 86 (47%)
 TNBC 58 (31%)
AntiHER2 Treatment among HER2-positive patients (N=86)  
 Before BM diagnosis 47 (51%)
  as an adjuvant treatment 12
  as a neoadjuvant treatment 1
  as a palliative treatment 34
 After BM diagnosis 15 (17%)
 No anti-HER2 treatment 24 (32%)
Overall Survival, median months  
 from initial distant metastases (mOS) 23.3
 from initial BM diagnosis (BM-OS) 9.6